Effect of the specific proteasome inhibitor bortezomib on cancer-related muscle wasting

Journal of Cachexia, Sarcopenia and Muscle

Volumn , Issue , 2016, Pages 345-354

  Penna, Fabio ^a   Bonetto, Andrea ^b   Aversa, Zaira ^c   Minero, Valerio Giacomo ^a,d   Rossi Fanelli, Filippo ^c   Costelli, Paola ^a   Muscaritoli, Maurizio ^c  

^a UNIVERSITY OF TURIN   (Italy)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

Author keywords

Bortezomib; Cancer cachexia; Muscle wasting; Proteasome

Indexed keywords

ATROGIN 1; BECLIN 1; BORTEZOMIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MUSCLE RING FINGER 1 PROTEIN; PROTEASOME;

AH 130 CELL LINE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES HEPATOMA; AUTOPHAGY; CACHEXIA; CARCINOMA CELL LINE; COLON ADENOCARCINOMA; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FOOD INTAKE; GASTROCNEMIUS MUSCLE; GENE EXPRESSION; MALE; MOUSE; MUSCLE ATROPHY; MUSCLE MASS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; RAT; SINGLE DRUG DOSE; SKELETAL MUSCLE; WEIGHT REDUCTION;

EID: 84978803205     PISSN: 21905991     EISSN: 21906009     Source Type: Journal    
DOI: 10.1002/jcsm.12050     Document Type: Article

References (67)

1. Muscaritoli M, Molfino A, Gioia G, Laviano A, Rossi Fanelli F . The “parallel pathway”: a novel nutritional and metabolic approach to cancer patients. Intern Emerg Med 2011;6:105–12.
2. Muscaritoli M, Bossola M, Aversa Z, Bellantone R, Rossi Fanelli F . Prevention and treatment of cancer cachexia: new insight into an old problem. Eur J Cancer 2006;42:31–41.
3. Acharyya S, Guttridge DC . Cancer cachexia signaling pathways continue to emerge yet much still points to the proteasome. Clin Cancer Res 2007;13:1356–61.
4. Penna F, Baccino FM, Costelli P . Coming back: autophagy in cachexia. Curr Opin Clin Nutr Metab Care 2014;17:241–6.
5. Ciechanover A . The ubiquitin-proteasome proteolytic pathway. Cell 1994;79:13–21.
6. Kisselev AF, Goldberg AL . Proteasome inhibitors: from research tools to drug candidates. Chem Biol 2001;8:739–58.
7. Crawford LJ, Walker B, Irvine AE . Proteasome inhibitors in cancer therapy. J Cell Commun Signal 2011;5:101–10.
8. Fischer D, Gang G, Pritts T, Hasselgren PO . Sepsis-induced muscle proteolysis is prevented by a proteasome inhibitor in vivo . Biochem Biophys Res Commun 2000;270:215–21.
9. Fang CH, Wang JJ, Hobler S, Li BG, Fischer JE, Hasselgren PO . Proteasome blockers inhibit protein breakdown in skeletal muscle after burn injury in rats. Clin Sci (Lond) 1998;95:225–33.
10. Zhang L, Tang H, Kou Y, Li R, Zheng Y, Wang Q, et al. MG132-mediated inhibition of the ubiquitin-proteasome pathway ameliorates cancer cachexia. J Cancer Res Clin Oncol 2013a;139:1105–15.
11. Caron AZ, Haroun S, Leblanc E, Trensz F, Guindi C, Amrani A, et al. The proteasome inhibitor MG132 reduces immobilization-induced skeletal muscle atrophy in mice. BMC Musculoskelet Disord 2011;12:185.
12. Tawa NE Jr, Odessey R, Goldberg AL . Inhibitors of the proteasome reduce the accelerated proteolysis in atrophying rat skeletal muscles. J Clin Invest 1997;100:197–203.
13. Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP . Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets 2011;11:239–53.
14. Elliott PJ, Ross JS . The proteasome: a new target for novel drug therapies. Am J Clin Pathol 2001;116:637–46.
15. Schwartz R, Davidson T . Pharmacology, pharmacokinetics, and practical applications of bortezomib. Oncology (Williston Park) 2004;18:14–21.
16. Dick LR, Fleming PE . Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. Drug Discov Today 2010;15:243–9.
17. Goldberg AL . Development of proteasome inhibitors as research tools and cancer drugs. Cell Biol 2012;199:583–8.
18. Kubiczkova L, Pour L, Sedlarikova L, Hajek R, Sevcikova S . Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma. J Cell Mol Med 2014;18:947–61.
19. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609–17.
20. Kane RC, Farrell AT, Sridhara R, Pazdur R . United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin Cancer Res 2006;12:2955–60.
21. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906–17.
22. Mateos MV, Richardson PG, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 2010;28:2259–66.
23. Kane RC, Dagher R, Farrell A, Ko CW, Sridhara R, Justice R, et al. Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res 2007;13:5291–4.
24. Buac D, Shen M, Schmitt S, Kona FR, Deshmukh R, Zhang Z, et al. From bortezomib to other inhibitors of the proteasome and beyond. Curr Pharm Des 2013;19:4025–38.
25. Bose P, Batalo MS, Holkova B, Grant S . Bortezomib for the treatment of non-Hodgkin's lymphoma. Expert Opin Pharmacother 2014;15:2443–59.
26. Herrera AF, Kim HT, Bindra B, Jones KT, Alyea EP 3rd, Armand P, et al. A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2014;20:1737–43.
27. Pai CC, Chen M, Mirsoian A, Grossenbacher SK, Tellez J, Ames E, et al. Treatment of chronic graft-versus-host disease with bortezomib. Blood 2014;124:1677–88.
28. Skrott Z, Cvek B . Linking the activity of bortezomib in multiple myeloma and autoimmune diseases. Crit Rev Oncol Hematol 2014;92:61–70.
29. Lang CH, Huber D, Frost RA . Burn-induced increase in atrogin-1 and MuRF-1 in skeletal muscle is glucocorticoid independent but downregulated by IGF-I. Am J Physiol Regul Integr Comp Physiol 2007;292:R328–36.
30. Beehler BC, Sleph PG, Benmassaoud L, Grover GJ . Reduction of skeletal muscle atrophy by a proteasome inhibitor in a rat model of denervation. Exp Biol Med (Maywood) 2006;231:335–41.
31. van Hees H, Ottenheijm C, Ennen L, Linkels M, Dekhuijzen R, Heunks L . Proteasome inhibition improves diaphragm function in an animal model for COPD. Am J Physiol Lung Cell Mol Physiol 2011;301:L110–6.
32. Bonuccelli G, Sotgia F, Capozza F, Gazzerro E, Minetti C, Lisanti MP . Localized treatment with a novel FDA-approved proteasome inhibitor blocks the degradation of dystrophin and dystrophin-associated proteins in mdx mice. Cell Cycle 2007;6:1242–8.
33. Gazzerro E, Assereto S, Bonetto A, Sotgia F, Scarfì S, Pistorio A, et al. Therapeutic potential of proteasome inhibition in Duchenne and Becker muscular dystrophies. Am J Pathol 2010;176:1863–77.
34. Krawiec BJ, Frost RA, Vary TC, Jefferson LS, Lang CH . Hindlimb casting decreases muscle mass in part by proteasome-dependent proteolysis but independent of protein synthesis. Am J Physiol Endocrinol Metab 2005;289:E969–80.
35. Supinski GS, Vanags J, Callahan LA . Effect of proteasome inhibitors on endotoxin-induced diaphragm dysfunction. Am J Physiol Lung Cell Mol Physiol 2009;296:L994–L1001.
36. Chacon-Cabrera A, Fermoselle C, Urtreger AJ, Mateu-Jimenez M, Diament MJ, de Kier Joffé ED, et al. Pharmacological strategies in lung cancer-induced cachexia: effects on muscle proteolysis, autophagy, structure, and weakness. J Cell Physiol 2014;229:1660–72.
37. Fermoselle C, García-Arumí E, Puig-Vilanova E, Andreu AL, Urtreger AJ, de KierJoffé ED, et al. Mitochondrial dysfunction and therapeutic approaches in respiratory and limb muscles of cancer cachectic mice. Exp Physiol 2013;98:1349–65.
38. Jatoi A, Alberts SR, Foster N, Morton R, Burch P, Block M, et al. Is bortezomib, a proteasome inhibitor, effective in treating cancer-associated weight loss? Preliminary results from the North Central Cancer Treatment Group. Support Care Cancer 2005;13:381–6.
39. Bossola M, Muscaritoli M, Costelli P, Bellantone R, Pacelli F, Busquets S, et al. Increased muscle ubiquitin mRNA levels in gastric cancer patients. Am J Physiol Regul Integr Comp Physiol 2001;280:R1518–23.
40. Bossola M, Muscaritoli M, Costelli P, Grieco G, Bonelli G, Pacelli F, et al. Increased muscle proteasome activity correlates with disease severity in gastric cancer patients. Ann Surg 2003;237:384–9.
41. Tardif N, Klaude M, Lundell L, Thorell A, Rooyackers O . Autophagic-lysosomal pathway is the main proteolytic system modified in the skeletal muscle of esophageal cancer patients. Am J Clin Nutr 2013;98:1485–92.
42. Op den Kamp CM, Langen RC, Minnaard R, Kelders MC, Snepvangers FJ, Hesselink MK, et al. Pre-cachexia in patients with stages I-III non-small cell lung cancer: systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system. Lung Cancer 2012;76:112–7.
43. Baracos VE, DeVivo C, Hoyle DH, Goldberg AL . Activation of the ATP-ubiquitin-proteasome pathway in skeletal muscle of cachectic rats bearing a hepatoma. Am J Physiol 1995;268:E996–1006.
44. Costelli P, Bossola M, Muscaritoli M, Grieco G, Bonelli G, Bellantone R, et al. Anticytokine treatment prevents the increase in the activity of ATP-ubiquitin- and Ca(2+)-dependent proteolytic systems in the muscle of tumour-bearing rats. Cytokine 2002;19:1–5.
45. Costelli P, Muscaritoli M, Bossola M, Penna F, Reffo P, Bonetto A, et al. IGF-1 is downregulated in experimental cancer cachexia. J Physiol Regul Integr Comp Physiol 2006;291:R674–83.
46. Mastrocola R, Reffo P, Penna F, Tomasinelli CE, Boccuzzi G, Baccino FM, et al. Muscle wasting in diabetic and in tumor-bearing rats: role of oxidative stress. Free Radic Biol Med 2008;44:584–93.
47. Acharyya S, Butchbach ME, Sahenk Z, Wang H, Saji M, Carathers M, et al. Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia. Cancer Cell 2005;8:421–32.
48. Aulino P, Berardi E, Cardillo VM, Rizzuto E, Perniconi B, Ramina C, et al. Molecular, cellular and physiological characterization of the cancer cachexia-inducing C26 colon carcinoma in mouse. BMC Cancer 2010;10:363.
49. Costelli P, Muscaritoli M, Bonetto A, Penna F, Reffo P, Bossola M, et al. Muscle myostatin signalling is enhanced in experimental cancer cachexia. Eur J Clin Invest 2008;38:531–538.
50. Fang J, Rhyasen G, Bolanos L, Rasch C, Varney M, Wunderlich M, et al. Cytotoxic effects of bortezomib in myelodysplastic syndrome/acutemyeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1. Blood 2012;120:858–67.
51. Li C, Johnson DE . Bortezomib induces autophagy in head and neck squamous cell carcinoma cells via JNK activation. Cancer Lett 2012;314:102–7.
52. Granato M, Santarelli R, Lotti LV, Di Renzo L, Gonnella R, Garufi A, et al. JNK and macroautophagy activation by bortezomib has a pro-survival effect in primary effusion lymphoma cells. PLoS One 2013;8:e75965.
53. Min H, Xu M, Chen ZR, Zhou JD, Huang M, Zheng K, et al. Bortezomib induces protective autophagy through AMP-activated protein kinase activation in cultured pancreatic and colorectal cancer cells. Cancer Chemother Pharmacol 2014;74:167–76.
54. Periyasamy-Thandavan S, Jackson WH, Samaddar JS, Erickson B, Barrett JR, Raney L, et al. Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress and induces caspase-dependent cell death in antiestrogen-sensitive and resistant ER+ breast cancer cells. Autophagy 2010;6:19–35.
55. Kao C, Chao A, Tsai CL, Chuang WC, Huang WP, Chen GC, et al. Bortezomib enhances cancer cell death by blocking the autophagic flux through stimulating ERK phosphorylation. Cell Death Dis 2014;5:e1510.
56. Funderburk SF, Wang QJ, Yue Z . The beclin 1-VPS34 complex: at the crossroads of autophagy and beyond. Trends Cell Biol 2010;20:355e362.
57. Bonetto A, Penna F, Minero VG, Reffo P, Bonelli G, Baccino FM, et al. Deacetylase inhibitors modulate the myostatin/follistatin axis without improving cachexia in tumor-bearing mice. Curr Cancer Drug Targets 2009;9:608–16.
58. Costelli P, Reffo P, Penna F, Autelli R, Bonelli G, Baccino FM . Ca(2+)-dependent proteolysis in muscle wasting. Int J Biochem Cell Biol 2005;37:2134–46.
59. Penna F, Costamagna D, Pin F, Camperi A, Fanzani A, Chiarpotto EM, et al. Autophagic degradation contributes to muscle wasting in cancer cachexia. Am J Pathol 2013;182:1367–78.
60. Sandri M . Protein breakdown in muscle wasting: role of autophagy-lysosome and ubiquitine proteasome. Int J Biochem Cell Biol 2013;45:2121–2129.
61. Wing SS . Deubiquitinases in skeletal muscle atrophy. Int J Biochem Cell Biol 2013;45:2130–5.
62. Zhang L, Tang H, Kou Y, Li R, Zheng Y, Wang Q, et al. MG132-mediated inhibition of the ubiquitin-proteasome pathway ameliorates cancer cachexia. J Cancer Res Clin Oncol 2013b;139:1105–15.
63. Xing SS, Shen CC, Godard MP, Wang JJ, Yue YY, Yang ST, et al. Bortezomib inhibits C2C12 growth by inducing cell cycle arrest and apoptosis. Biochem Biophys Res Commun 2014;445:375–80.
64. Cavaletti G, Jakubowiak AJ . Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies. Leuk Lymphoma 2010 Jul;51:1178–87.
65. Enrico O, Gabriele B, Nadia C, Sara G, Daniele V, Giulia C, et al. Unexpected cardiotoxicity in haematological bortezomib treated patients. Br J Haematol 2007;138:396–7.
66. Nowis D, Maczewski M, Mackiewicz U, Kujawa M, Ratajska A, Wieckowski MR, et al. Cardiotoxicity of the anticancer therapeutic agent bortezomib. Am J Pathol 2010;176:2658–68.
67. Xiao Y, Yin J, Wei J, Shang Z . Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: a systematic review and meta-analysis. PLoS One 2014;9:e87671.